Talphera, INC

Talphera announced Q2 2026 results, highlighting 75% enrollment in its NEPHRO CRRT study and positive inclusion of nafamostat in draft KDIGO guidelines, alongside an increased market size estimate.

Talphera announced its first quarter 2026 financial results, highlighting progress in its NEPHRO CRRT clinical study and a cash balance of $21.1 million.

Talphera, Inc. announced its fourth quarter and full year 2025 financial results, highlighted by 50% enrollment in its NEPHRO CRRT clinical study and a $4.1 million financing tranche.

Talphera, Inc. announced the completion of the third closing of its private placement, raising approximately $4.1 million in gross proceeds.

Talphera, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Talphera, Inc. announced third quarter 2025 financial results, including a $17 million financing tranche and an extended cash runway through potential Niyad PMA approval in late 2026, alongside progress in its NEPHRO study.

Talphera, Inc. reported a net loss of $4.3 million for Q2 2026, with cash reserves dwindling, raising concerns about its ability to fund operations beyond the next twelve months.

Talphera, Inc. filed its Q1 2026 Form 10-Q, detailing ongoing development efforts for Niyad, continued net losses, and a need for additional capital, while also addressing a Nasdaq minimum bid price deficiency.

Talphera, Inc. reported a reduced net loss for the nine months ended September 30, 2025, bolstered by recent capital raises totaling $21.3 million, but continues to face substantial doubt about its ability to continue as a going concern.

Talphera, Inc. reported continued net losses and negative cash flows for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite efforts to reduce operating expenses and secure new financing.

Talphera Inc. announces its Q1 2025 financial results, highlighting a net loss of $2.6 million and ongoing efforts to advance its Niyad program while addressing concerns about its ability to continue as a going concern.

Talphera Inc. reported its Q3 2024 results, highlighting a net loss of $3.4 million and a strategic focus on the development of its Niyad product candidate, while navigating ongoing financial constraints.

Talphera, Inc. reported a net loss of $14.3 million for 2025, raising substantial doubt about its ability to continue as a going concern, despite focusing resources on its lead product candidate, Niyad.

Talphera, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include updated information on directors, executive officers, corporate governance, executive compensation, and related matters.

Talphera, Inc.'s FY 2024 10-K filing reveals ongoing financial losses and a need for additional capital, balanced by progress in product development and strategic divestments.

Talphera, Inc.'s 10-K filing reveals ongoing losses and a need for additional capital, raising doubts about the company's ability to continue as a going concern.

Talphera Director Mark A. Wan acquired 5,100 shares of common stock and 30,700 stock options, with vesting contingent on continued service.

Director Joseph Todisco of Talphera, Inc. reported the acquisition of 5,100 shares of common stock and 30,700 stock options.

Talphera, Inc. director Abhinav Jain reported the acquisition of 5,100 shares of common stock and 30,700 stock options.

Talphera, Inc. director Stephen J. Hoffman acquired 5,100 shares of common stock and was granted an option for 30,700 shares.

Jill Marie Broadfoot, a Director at Talphera, Inc., acquired 5,100 shares of common stock and was granted an option for 30,700 shares.

Director Marina Bozilenko acquired 5,100 shares of common stock and 30,700 stock options in Talphera, Inc. (TLPH) on June 22, 2026.

Talphera, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 22, 2026, to elect directors and vote on equity plans.

Talphera, Inc. has filed definitive additional proxy materials with the U.S. Securities and Exchange Commission.

Talphera, Inc. will hold its annual meeting to vote on a reverse stock split, expanded equity incentive plans, and executive compensation amidst efforts to regain Nasdaq compliance.

Talphera, Inc. files a definitive proxy statement with the Securities and Exchange Commission.

Talphera, Inc. is holding its annual meeting of stockholders on June 24, 2024, to vote on director elections, auditor ratification, executive compensation, and equity incentive plan approvals.

CorMedix Inc. has acquired a significant stake in Talphera, Inc. and secured exclusive negotiation rights for a potential full acquisition, contingent on clinical trial results.

Talphera, Inc. has entered into a Securities Purchase Agreement to raise up to approximately $7.5 million through the issuance of pre-funded warrants and common stock, with subsequent tranches contingent on clinical trial progress and stock price performance.

Nantahala Capital Management, LLC, along with its principals, has increased its beneficial ownership in Talphera, Inc. to 11.7% through a pre-funded warrant purchase and committed to additional investments contingent on clinical trial patient enrollment and stock price performance.

Rosalind Advisors, Inc. and its affiliates have filed a Schedule 13G, reporting a beneficial ownership of 9.9% in Talphera, Inc., with significant holdings subject to exercise blockers.

Laurence W. Lytton and Lytton-Kambara Foundation report a combined 5% stake in Talphera Inc. as of March 31, 2026.

Rosalind Advisors, Inc. and related entities have reported beneficial ownership of 9.9% of Talphera, Inc.'s common stock as of March 31, 2025.

Laurence W. Lytton and the Lytton-Kambara Foundation jointly reported a 5.9% beneficial ownership stake in Talphera, Inc. common stock.

Rosalind Advisors and its associated entities reported a 9.9% beneficial ownership stake in Talphera, Inc., primarily through common stock, warrants, and pre-funded warrants.

AIGH Capital Management and Orin Hirschman have disclosed a 9.8% beneficial ownership stake in Talphera, Inc., holding 4,661,502 shares.